Drug intelligence / Profile preview

glucocorticoid + recombinant human thrombopoietin

Development stage: Unknown
Lead developer: 3SBio
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

A combination therapy consisting of glucocorticoids and recombinant human thrombopoietin (rhTPO). This combination is primarily used for treating immune thrombocytopenia (ITP) and has shown enhanced efficacy compared to glucocorticoids alone. The therapy works by promoting platelet production through rhTPO while modulating immune response through glucocorticoids. Clinical studies have demonstrated higher response rates, faster platelet count recovery, and improved T lymphocyte regulation with this combination.

Other names: rhTPO + glucocorticoids

Targets

GR (Glucocorticoid receptor)TPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on glucocorticoid + recombinant human thrombopoietin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glucocorticoid + recombinant human thrombopoietin.

Explore the full profile